SELLAS Life Sciences Group Inc buy quelbe60
Start price
24.02.23
/
50%
€1.59
Target price
24.02.24
-
Performance (%)
-4.83%
End price
04.03.23
€1.52
Summary
This prediction ended on 04.03.23 with a price of €1.52. With a performance of -4.83%, the BUY prediction by quelbe60 finished with a loss. quelbe60 has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
SELLAS Life Sciences Group Inc | 1.520% | 1.520% | -13.150% |
iShares Core DAX® | 1.937% | 1.473% | 18.596% |
iShares Nasdaq 100 | -1.186% | -0.040% | 27.123% |
iShares Nikkei 225® | 1.938% | 4.205% | 17.502% |
iShares S&P 500 | -0.023% | 0.109% | 24.843% |
Comments by quelbe60 for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Buy SELLAS Life Sciences Group Inc
In the thread Trading SELLAS Life Sciences Group Inc
Buy beendet
Stopped prediction by quelbe60 for SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€2.15
15.11.22
15.11.22
-
15.11.23
15.11.23
-26.97%
24.02.23
24.02.23
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€6.57
10.12.20
10.12.20
€5.00
0.52%
14.12.20
14.12.20